Answers are grounded in this paper and cite their sources.
Observational analysis highlights therapeutic modulation of RNA splicing factors in multiple myeloma, suggesting novel treatment strategies.
In this issue of Blood Cancer Discovery, Kamiya and colleagues identify aberrant RNA splicing as a targetable vulnerability in multiple myeloma. Using the RBM39 degrader indisulam, they show that therapeutic modulation of RNA splicing factors is a potential treatment strategy for patients with therapy-resistant multiple myeloma. See related article by Kamiya et al., p. XX.
No takes yet. Share an insight, caveat, or question.
Maron et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: